GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » EV-to-EBITDA

Lyka Labs (BOM:500259) EV-to-EBITDA : 25.93 (As of May. 18, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lyka Labs's enterprise value is ₹4,596 Mil. Lyka Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹177 Mil. Therefore, Lyka Labs's EV-to-EBITDA for today is 25.93.

The historical rank and industry rank for Lyka Labs's EV-to-EBITDA or its related term are showing as below:

BOM:500259' s EV-to-EBITDA Range Over the Past 10 Years
Min: -278.53   Med: 8.54   Max: 365.26
Current: 25.92

During the past 13 years, the highest EV-to-EBITDA of Lyka Labs was 365.26. The lowest was -278.53. And the median was 8.54.

BOM:500259's EV-to-EBITDA is ranked worse than
75.6% of 455 companies
in the Biotechnology industry
Industry Median: 10.35 vs BOM:500259: 25.92

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-18), Lyka Labs's stock price is ₹115.30. Lyka Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-1.240. Therefore, Lyka Labs's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Lyka Labs EV-to-EBITDA Historical Data

The historical data trend for Lyka Labs's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs EV-to-EBITDA Chart

Lyka Labs Annual Data
Trend Mar13 Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.06 -14.45 11.62 5.33 30.37

Lyka Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.70 30.37 43.05 65.45 23.24

Competitive Comparison of Lyka Labs's EV-to-EBITDA

For the Biotechnology subindustry, Lyka Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lyka Labs's EV-to-EBITDA falls into.



Lyka Labs EV-to-EBITDA Calculation

Lyka Labs's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4596.221/177.287
=25.93

Lyka Labs's current Enterprise Value is ₹4,596 Mil.
Lyka Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹177 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyka Labs  (BOM:500259) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Lyka Labs's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=115.30/-1.240
=At Loss

Lyka Labs's share price for today is ₹115.30.
Lyka Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Lyka Labs EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lyka Labs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs (BOM:500259) Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines